^
    1d
    Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma. (PubMed, Hemasphere)
    Daratumumab-mediated disruption of mitochondrial transfer reduced the mitochondrial content in MM cells, prevented the boost in OXPHOS, significantly impaired MM cell growth and migration, and mitigated drug-resistance. In conclusion, we reveal a crucial metabolic interplay between monocytes and MM cells within the BM microenvironment that promotes tumor growth and induces therapy resistance, providing the rationale for treatment strategies that combine targeting tumor metabolism with existing anti-MM agents.
    Journal • IO biomarker
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    Darzalex (daratumumab)
    1d
    A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1/2, N=159, Not yet recruiting, Sinocelltech Ltd.
    New P1/2 trial
    6d
    REMAKE: REal World MAIA UK OutcomEs (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, The Royal Wolverhampton Hospitals NHS Trust
    New trial • Real-world evidence
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone
    7d
    EMN37 fitfix: Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. (clinicaltrials.gov)
    P2, N=150, Recruiting, European Myeloma Network B.V. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Darzalex (daratumumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    7d
    PREVAIL: A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) (clinicaltrials.gov)
    P3, N=454, Recruiting, Biogen
    Trial initiation date
    |
    felzartamab (MOR202)
    8d
    FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Medical College of Wisconsin | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    Darzalex (daratumumab)
    8d
    DarTTP: Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Darzalex (daratumumab)
    8d
    MonumenTAL-3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (clinicaltrials.gov)
    P3, N=864, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2029 --> May 2028 | Trial primary completion date: Feb 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • dexamethasone injection
    9d
    MajesTEC-7: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=1590, Recruiting, Janssen Research & Development, LLC | N=568 --> 1590
    Enrollment change
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    9d
    AQUARIUS: A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=151, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2027 --> Oct 2026
    Trial completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    13d
    TAK-079-1002: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov)
    P1, N=50, Completed, Takeda | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • bortezomib • dexamethasone • pomalidomide • mezagitamab (TAK-079)
    14d
    TAK-079-3002: A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P3, N=171, Recruiting, Takeda | N=101 --> 171
    Enrollment change
    |
    mezagitamab (TAK-079)